Survodutide

Summary

Survodutide (CHEMBL5314776) is a phase-3 clinical-stage protein targeting GLP1R and GCGR; indicated across 2 conditions including obesity disorder and metabolic dysfunction-associated steatotic liver disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Targets: 2 (GLP1R, GCGR)
• Indications: 2 conditions
• Clinical trials: 25

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314776
Name	Survodutide
Type	Protein
Max phase	3

Also known as: BI 456906, BI-456906, BI456906, Survodutida, Survodutide, SURVODUTIDE

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GLP1R	GLP-1 receptor	Agonist	9.48	0.2%	P43220
GCGR	glucagon receptor	Agonist	9.28	0.2%	P47871

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): GLP1R, GCGR.

Top Reactome pathways

5 total, by targets touching each:

Pathway	Targets	Genes
G alpha (s) signalling events	2	GCGR, GLP1R
Glucagon-type ligand receptors	2	GCGR, GLP1R
Glucagon signaling in metabolic regulation	1	GCGR
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion	1	GLP1R
G alpha (q) signalling events	1	GCGR

Dominant GO biological processes

GO term	Targets
cell surface receptor signaling pathway	2
adenylate cyclase-activating G protein-coupled receptor signaling pathway	2
signal transduction	2
G protein-coupled receptor signaling pathway	2
cellular response to glucagon stimulus	2
activation of adenylate cyclase activity	1
positive regulation of cytosolic calcium ion concentration	1
learning or memory	1
regulation of heart contraction	1
post-translational protein targeting to membrane, translocation	1
negative regulation of blood pressure	1
positive regulation of blood pressure	1
hormone secretion	1
response to psychosocial stress	1
regulation of biological quality	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
obesity disorder	1	MONDO:0011122	EFO:0001073
metabolic dysfunction-associated steatotic liver disease	1	MONDO:0013209	EFO:0003095

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
PHASE1	14
PHASE3	8
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06077864	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06632444	PHASE3	RECRUITING	LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632457	PHASE3	RECRUITING	LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06066515	PHASE3	COMPLETED	A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT06066528	PHASE3	COMPLETED	A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06176365	PHASE3	COMPLETED	A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
NCT06214741	PHASE3	COMPLETED	A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
NCT06309992	PHASE3	COMPLETED	A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
NCT04153929	PHASE2	COMPLETED	A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
NCT04667377	PHASE2	COMPLETED	A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
NCT04771273	PHASE2	COMPLETED	A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
NCT05202353	PHASE1	RECRUITING	A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
NCT06745284	PHASE1	ACTIVE_NOT_RECRUITING	A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity
NCT07221591	PHASE1	ACTIVE_NOT_RECRUITING	A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
NCT03175211	PHASE1	COMPLETED	Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers
NCT03591718	PHASE1	COMPLETED	A Study to Test Different Doses of BI 456906 in Patients With Obesity
NCT04384081	PHASE1	COMPLETED	A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2
NCT05296733	PHASE1	COMPLETED	A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906
NCT05751226	PHASE1	COMPLETED	A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906
NCT05896384	PHASE1	COMPLETED	A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
NCT06200467	PHASE1	COMPLETED	A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity
NCT06352411	PHASE1	COMPLETED	A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems
NCT06352424	PHASE1	COMPLETED	A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
NCT06492135	PHASE1	COMPLETED	A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body
NCT06564441	PHASE1	COMPLETED	A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

41 molecules share ≥1 primary target. Top 41 by shared-target count:

Molecule	Source	Status	Shared targets
Dihydroergotamine	ChEMBL + PubChem	Phase 4 (approved)	GCGR, GLP1R
GLUCAGON	ChEMBL	Phase 4 (approved)	GCGR, GLP1R
COTADUTIDE	ChEMBL	Phase 2	GCGR, GLP1R
PF-06291874	ChEMBL	Phase 2	GCGR, GLP1R
LIRAGLUTIDE	ChEMBL + PubChem	Phase 4 (approved)	GLP1R
ELAGOLIX	ChEMBL	Phase 4 (approved)	GLP1R
EXENATIDE	ChEMBL	Phase 4 (approved)	GLP1R
LOPERAMIDE	ChEMBL	Phase 4 (approved)	GLP1R
PERPHENAZINE	ChEMBL	Phase 4 (approved)	GLP1R
SECRETIN	ChEMBL	Phase 4 (approved)	GLP1R
SEMAGLUTIDE	ChEMBL	Phase 4 (approved)	GLP1R
TIRZEPATIDE	ChEMBL	Phase 4 (approved)	GLP1R
TOLVAPTAN	ChEMBL	Phase 4 (approved)	GLP1R
ORFORGLIPRON	ChEMBL	Phase 3	GLP1R
ADOMEGLIVANT	ChEMBL	Phase 2	GCGR
DANUGLIPRON	ChEMBL	Phase 2	GLP1R
DEVAZEPIDE	ChEMBL	Phase 2	GLP1R
GLP-1	ChEMBL	Phase 2	GLP1R
LOTIGLIPRON	ChEMBL	Phase 2	GLP1R
MK-0893	ChEMBL	Phase 2	GCGR
MK-3577	ChEMBL	Phase 2	GCGR
Aclidinium Bromide	PubChem	Approved	GCGR
Acyclovir	PubChem	Approved	GCGR
Allopurinol	PubChem	Approved	GCGR
Alogliptin	PubChem	Approved	GCGR
Bosentan	PubChem	Approved	GCGR
Clozapine	PubChem	Approved	GCGR
Crizotinib	PubChem	Approved	GCGR
Desloratadine	PubChem	Approved	GCGR
Ethambutol	PubChem	Approved	GCGR
Fidaxomicin	PubChem	Approved	GCGR
Methotrexate	PubChem	Approved	GCGR
Olanzapine	PubChem	Approved	GCGR
Olmesartan Medoxomil	PubChem	Approved	GCGR
Propoxyphene	PubChem	Approved	GCGR
Pyrazinamide	PubChem	Approved	GCGR
rifampin	PubChem	Approved	GCGR
Sildenafil	PubChem	Approved	GCGR
Tegaserod	PubChem	Approved	GCGR
Tiotropium Bromide Monohydrate	PubChem	Approved	GCGR
Valacyclovir	PubChem	Approved	GCGR